By mid-year, Mass. life science M&A tops $22.5B

//By mid-year, Mass. life science M&A tops $22.5B

By mid-year, Mass. life science M&A tops $22.5B

Midway through 2019, more than a dozen local biotechs and medical device firms have made business sales, acquisitions or merged with other companies. Thermo Fisher Scientific, Boston Scientific Corp., Vertex, Biogen and others have all announced or completed deals since the start of the year. These transactions reached $22.5 billion in collective value, ranging from just a few million for a reverse-merger that gave one company the ability to launch on the stock market to several billion dollars…

Article by [author-name] (c) Health Care News - Health Care News Headlines | Bizjournals.com - Read full story here.

By | 2019-07-10T09:23:29+00:00 July 10th, 2019|Healthcare|

About the Author: